Retatrutide is a new pharmaceutical in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By activating these receptors, https://laylaeiaa175434.digitollblog.com/36027405/setmelanotide-a-promising-new-treatment-for-obesity